Post-Conference Report
Our Post-Conference Report offers an in-depth analysis and summary of the 177 gene therapy-related abstracts presented at the 2024 ASGCT Annual Meeting. This report is an essential resource for staying updated on the latest developments and innovations in the field.
Highlights include:
- Analysis of the abstracts by the delivery system being investigated, top 10 diseases, and trial phase.
- A comprehensive summary of each abstract, including trial sponsor, delivery system, trial results, and safety outcomes.
- Convenient links to corresponding drug and trial pages on Beacon ensure easy access to further information.
We hope you find this report useful and insightful. We are as excited as we are to see the latest developments in gene therapy.
Pre-Conference Planner
Prepare for the 2024 ASGCT Annual Meeting with our Pre-Conference Planner. This essential tool provides a comprehensive overview of the gene therapy abstracts, organized to help you easily navigate the conference.
Features include:
- Detailed information on 43 clinical studies, 126 preclinical studies, and 3 that are both clinical and preclinical.
- Organized by presentation sequence to streamline your conference experience.
- Essential details for each abstract including ID, title, trial ID, sponsor, time, and location.
Maximize your conference experience with our pre-conference planner, designed to ensure you don’t miss any critical presentations and can effectively plan your schedule.
Beacon Gene Therapy
How the most complete gene therapy database can help you
What we cover
We included trial and drug records for preclinical, active, approved, and discontinued:
- RNA/DNA Viral vector-based therapies
- DNA Non-viral vector-based therapies
- Genetically Modified cell therapies
- Empty Vector Trials
- Other comparable modalities within gene therapy, whether cell-free or cell-based
- Beacon Gene Therapy covers all genetically driven non-oncology indications that utilize gene therapy to mediate the condition.
How Beacon Gene Therapy works
Search the clinical trial and drug landscape by gene/mutation, editing technology (CRISPR/Cas9, Cas-CLOVER, etc.), gene delivery system, promoter, etc., instantaneously and/or extract the data points you need to conduct more complex analysis.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the gene therapy space.
If publicly available, information regarding immunogenicity is included (unique to Beacon Gene Therapy)
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
At Beacon, we are committed to empowering our pharmaceutical and biotech industry partners with accurate, comprehensive data. We are not just a tool; we see ourselves as a partner in the drug development journey. Contact us to learn how we help you.
